Ann: Overall Survival data from ph IIb AIPAC breast cancer trial, page-36

ADR's on NASDAQ doing well - this from the australian 3 hrs ago:

9.02am:Immutep ADRs surge on trial results

Immutep ADRs more than doubled to $US5.10 a share in after-hours trading after reporting “encouraging” survival data from its lead cancer treatment eftiligimod alpha in combination with paclitaxel chemotherapy.

The biotech company reported a statistically significant survival benefit for a key patients group in its ongoing Phase 11b AIPAC study in metatastic breast cancer.

It’s the first time an antigen presenting cell (APC) activator has shown an overall survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy, the company says.

It notes a “promising and improving overall trend in OS in total population - based on approximately 60 per cent of events - with a median survival benefit of 2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo.

The data were selected to be presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, which is being held virtually this week from Texas, USA.